Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice.

Tabibiazar R, Wagner RA, Deng A, Tsao PS, Quertermous T.

Physiol Genomics. 2006 Apr 13;25(2):194-202. Epub 2006 Jan 17.

2.

Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice.

Lv S, Fan R, Du Y, Hou M, Tang Z, Ling W, Zhu H.

Eur J Nutr. 2009 Jun;48(4):205-12. doi: 10.1007/s00394-009-0003-4. Epub 2009 Mar 3.

PMID:
19255798
3.

Development of atherosclerosis in Balb/c apolipoprotein E-deficient mice.

Desai A, Zhao Y, Warren JS.

Cardiovasc Pathol. 2008 Jul-Aug;17(4):233-40. doi: 10.1016/j.carpath.2007.10.002. Epub 2007 Dec 3.

PMID:
18402814
5.

Mouse strain-specific differences in vascular wall gene expression and their relationship to vascular disease.

Tabibiazar R, Wagner RA, Spin JM, Ashley EA, Narasimhan B, Rubin EM, Efron B, Tsao PS, Tibshirani R, Quertermous T.

Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):302-8. Epub 2004 Nov 18.

6.

Murine cytomegalovirus infection increases aortic expression of proatherosclerotic genes.

Burnett MS, Durrani S, Stabile E, Saji M, Lee CW, Kinnaird TD, Hoffman EP, Epstein SE.

Circulation. 2004 Feb 24;109(7):893-7. Epub 2004 Feb 2.

7.

IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice.

Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, Song YH, Titterington J, Delafontaine P.

Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2684-90. Epub 2007 Oct 4.

8.

Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.

Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V.

Life Sci. 2008 Mar 26;82(13-14):708-17. doi: 10.1016/j.lfs.2008.01.006. Epub 2008 Jan 26.

PMID:
18289605
9.

Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease.

Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, Iribarren C, Tsao PS, Tabibiazar R, Quertermous T; ADVANCE Investigators.

Physiol Genomics. 2007 Nov 14;31(3):402-9. Epub 2007 Aug 14.

10.

Circulating levels of the chemokines JE and KC in female C3H apolipoprotein-E-deficient and C57BL apolipoprotein-E-deficient mice as potential markers of atherosclerosis development.

Parkin SL, Pritchett JP, Grimsditch DC, Bruckdorfer KR, Sahota PK, Lloyd A, Overend P, Benson GM.

Biochem Soc Trans. 2004 Feb;32(Pt 1):128-30.

PMID:
14748730
11.
12.

Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.

Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB.

Circulation. 2007 Apr 24;115(16):2178-87. Epub 2007 Apr 9.

13.

[Anti-atherosclerotic effect of betaine in apolipoprotein E-deficient mice].

Fan RX, Lü SW, DU YP, Hou MJ, Zhu HL.

Zhonghua Yu Fang Yi Xue Za Zhi. 2008 Oct;42(10):742-7. Chinese.

PMID:
19178837
14.

Atherosclerosis and the protective role played by different proteins in apolipoprotein E-deficient mice.

Fabrizio Rodella L, Bonomini F, Rezzani R, Tengattini S, Hayek T, Aviram M, Keidar S, Coleman R, Bianchi R.

Acta Histochem. 2007;109(1):45-51. Epub 2006 Oct 12.

PMID:
17046051
15.

Stem cell-related cardiac gene expression early after murine myocardial infarction.

Vandervelde S, van Luyn MJ, Rozenbaum MH, Petersen AH, Tio RA, Harmsen MC.

Cardiovasc Res. 2007 Mar 1;73(4):783-93. Epub 2006 Nov 29.

PMID:
17208206
16.

Temporal relationships between circulating levels of CC and CXC chemokines and developing atherosclerosis in apolipoprotein E*3 Leiden mice.

Murphy N, Bruckdorfer KR, Grimsditch DC, Overend P, Vidgeon-Hart M, Groot PH, Benson GM, Graham A.

Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1615-20. Epub 2003 Jul 3.

17.

Proteomic profiling in apolipoprotein E-deficient mice during atherosclerosis progression.

Dursun E, Ozben B, Monari E, Cuoghi A, Tomasi A, Ozben T.

Acta Histochem. 2010 Mar;112(2):178-88. doi: 10.1016/j.acthis.2008.10.007. Epub 2009 Feb 20.

PMID:
19230958
18.

Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.

Damås JK, Smith C, Øie E, Fevang B, Halvorsen B, Waehre T, Boullier A, Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, Taskén K, Frøland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P.

Arterioscler Thromb Vasc Biol. 2007 Mar;27(3):614-20. Epub 2006 Dec 14.

19.

Direct evidence for a crucial role of the arterial wall in control of atherosclerosis susceptibility.

Pei H, Wang Y, Miyoshi T, Zhang Z, Matsumoto AH, Helm GA, Tellides G, Shi W.

Circulation. 2006 Nov 28;114(22):2382-9. Epub 2006 Nov 13.

20.

Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data.

Wang SS, Schadt EE, Wang H, Wang X, Ingram-Drake L, Shi W, Drake TA, Lusis AJ.

Circ Res. 2007 Aug 3;101(3):e11-30. Epub 2007 Jul 19.

Supplemental Content

Support Center